Diplomat Pharmacy, Inc. (NYSE:DPLO) Director Jeffrey G. Park purchased 3,000 shares of the business’s stock in a transaction dated Monday, November 20th. The shares were bought at an average price of $15.46 per share, with a total value of $46,380.00. Following the purchase, the director now directly owns 7,640 shares of the company’s stock, valued at $118,114.40. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Diplomat Pharmacy, Inc. (NYSE DPLO) traded down $0.35 during trading hours on Friday, reaching $16.97. The company’s stock had a trading volume of 448,301 shares, compared to its average volume of 810,048. The stock has a market capitalization of $1,192.88, a PE ratio of 22.49, a price-to-earnings-growth ratio of 3.12 and a beta of 0.74. The company has a debt-to-equity ratio of 0.18, a current ratio of 1.34 and a quick ratio of 0.82. Diplomat Pharmacy, Inc. has a 1 year low of $12.25 and a 1 year high of $21.99.

Diplomat Pharmacy (NYSE:DPLO) last released its quarterly earnings data on Monday, November 6th. The company reported $0.25 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.15 by $0.10. The firm had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.16 billion. Diplomat Pharmacy had a return on equity of 8.30% and a net margin of 0.18%. Diplomat Pharmacy’s revenue was down 4.8% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.21 earnings per share. sell-side analysts anticipate that Diplomat Pharmacy, Inc. will post 0.85 EPS for the current fiscal year.

Several equities research analysts have recently commented on DPLO shares. BidaskClub cut Diplomat Pharmacy from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, October 17th. Needham & Company LLC restated a “buy” rating and set a $23.75 price target (up previously from $19.75) on shares of Diplomat Pharmacy in a research note on Wednesday, October 4th. Robert W. Baird restated a “buy” rating and set a $20.00 price target on shares of Diplomat Pharmacy in a research note on Sunday, September 17th. TheStreet upgraded Diplomat Pharmacy from a “d+” rating to a “c-” rating in a research note on Thursday, August 10th. Finally, Zacks Investment Research upgraded Diplomat Pharmacy from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Six analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. Diplomat Pharmacy presently has an average rating of “Hold” and a consensus target price of $20.19.

A number of large investors have recently added to or reduced their stakes in the business. Public Employees Retirement System of Ohio raised its position in Diplomat Pharmacy by 3,847.7% in the third quarter. Public Employees Retirement System of Ohio now owns 42,359 shares of the company’s stock worth $877,000 after acquiring an additional 41,286 shares in the last quarter. Sterling Capital Management LLC purchased a new position in Diplomat Pharmacy in the third quarter worth $2,283,000. Piedmont Investment Advisors LLC purchased a new position in Diplomat Pharmacy in the third quarter worth $216,000. Continental Advisors LLC raised its position in Diplomat Pharmacy by 30.5% in the third quarter. Continental Advisors LLC now owns 42,800 shares of the company’s stock worth $886,000 after acquiring an additional 10,000 shares in the last quarter. Finally, Point72 Asset Management L.P. purchased a new position in Diplomat Pharmacy in the third quarter worth $8,226,000. Hedge funds and other institutional investors own 67.74% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This story was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this story on another website, it was stolen and reposted in violation of international trademark & copyright laws. The legal version of this story can be accessed at https://www.thecerbatgem.com/2017/11/25/jeffrey-g-park-acquires-3000-shares-of-diplomat-pharmacy-inc-dplo-stock.html.

About Diplomat Pharmacy

Diplomat Pharmacy, Inc (Diplomat) operates a specialty pharmacy business, which stocks, dispenses and distributes prescriptions for various biotechnology and specialty pharmaceutical manufacturers. The Company operates through specialty pharmacy services segment. The Company’s primary focus is on medication management programs for individuals with chronic diseases, including oncology, immunology, hepatitis, multiple sclerosis, specialty infusion therapy, and various other serious and/or long-term conditions.

Receive News & Stock Ratings for Diplomat Pharmacy Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy Inc. and related stocks with our FREE daily email newsletter.